Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (**Currently Amended**): A method for identifying a substance capable of disrupting microtubule organising centre (MTOC) integrity, which method comprises

contacting an Asp polypeptide ~~having~~ consisting of the amino acid sequence shown in SEQ ID No. 1, or fragment thereof capable of forming and/or maintaining MTOCs in the absence of the substance, with a candidate substance in the presence of components required for MTOC formation and microtubule nucleation therefrom, and determining whether the substance disrupts MTOC integrity.

Claim 2 (**Original**): A method according to claim 1 wherein said components comprise KI-extracted centrosomes and an Asp-depleted soluble cellular extract.

Claim 3 (**Original**): A method according to claim 1 wherein said components comprise a partially purified centrosome preparation and tubulin.

Claims 4-14 (**Canceled**)

Claim 15 (**Previously Presented**): A process comprising the steps of:

(a) performing the method as in any one of claims 1, 2 or 3; and

(b) preparing a quantity of those one or more substances identified as being capable of disrupting MTOC integrity.

Claim 16 (**Previously Presented**): A process comprising the steps of:

(a) performing the method as in any one of claims 1, 2 or 3; and

(b) preparing a pharmaceutical composition comprising one or more substances identified as being capable of disrupting MTOC integrity.

Claim 17 (**Currently Amended**): The method of claim 1, wherein the ASP polypeptide ~~comprises~~ consists of the sequence shown in SEQ ID No.1.

Claim 18 (**Previously Presented**): The method of claim 1, wherein the fragment comprises an N-terminal domain selected from the group consisting of at least one $p34^{cdc2}$ consensus phosphorylation site, at least one MAP kinase consensus phosphorylation site, and at least one MPM2 epitope phosphorylation site.

Claim 19 (**Previously Presented**): The method of claim 18, wherein the fragment further comprises a central domain comprising a putative actin binding site.

Claim 20 (**Previously Presented**): The method of claim 18, wherein the fragment further comprises a C-terminal coiled-coiled domain having at least two IQ motifs.

Claim 21 (**Previously Presented**) The method of claim 1, wherein the ASP polypeptide has between about 1 to about 30 substitutions, wherein the ASP polypeptide has microtubule organising centre integrity.